RAS (HRAS, KRAS, and NRAS) is the most frequently mutated gene in human cancers, particularly in positions G12 and Q61, and, consequently, the inhibition of oncogenic signaling mediated by RAS has been a key challenge in the field of cancer biology. This evidence concerns the gene HRAS and cancer.